121 related articles for article (PubMed ID: 32536689)
21. Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis.
Yönal İ; Dağlar-Aday A; Akadam-Teker B; Yılmaz C; Nalçacı M; Yavuz AS; Sargın FD
Turk J Haematol; 2016 Jun; 33(2):94-101. PubMed ID: 25913509
[TBL] [Abstract][Full Text] [Related]
22. CXCR4 expression on transplanted peripheral blood CD34+ cells: relationship to engraftment after autologous transplantation in a cohort of multiple myeloma patients.
Hicks C; Isaacs A; Wong R; Chong BH
Ann Hematol; 2011 May; 90(5):547-55. PubMed ID: 20957366
[TBL] [Abstract][Full Text] [Related]
23. WT1 gene is overexpressed in myeloproliferative neoplasms, especially in myelofibrosis.
Cottin L; Riou J; Boyer F; Bouvier A; Zannetti A; Blouet A; Truchan-Graczyk M; Jouanneau-Courville R; Beucher A; Ribourtout B; Orvain C; Hunault-Berger M; Blanchet O; Ugo V; Luque Paz D
Blood Cells Mol Dis; 2019 Mar; 75():35-40. PubMed ID: 30612065
[TBL] [Abstract][Full Text] [Related]
24. Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders.
Passamonti F; Vanelli L; Malabarba L; Rumi E; Pungolino E; Malcovati L; Pascutto C; Morra E; Lazzarino M; Cazzola M
Haematologica; 2003 Oct; 88(10):1123-9. PubMed ID: 14555308
[TBL] [Abstract][Full Text] [Related]
25. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.
Barbui T; Thiele J; Vannucchi AM; Tefferi A
Blood Cancer J; 2015 Aug; 5(8):e337. PubMed ID: 26832847
[TBL] [Abstract][Full Text] [Related]
26. Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms.
Čokić VP; Mitrović-Ajtić O; Beleslin-Čokić BB; Marković D; Buač M; Diklić M; Kraguljac-Kurtović N; Damjanović S; Milenković P; Gotić M; Raj PK
Mediators Inflamm; 2015; 2015():453020. PubMed ID: 26491227
[TBL] [Abstract][Full Text] [Related]
27. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.
Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M
Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873
[TBL] [Abstract][Full Text] [Related]
28. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
[TBL] [Abstract][Full Text] [Related]
29. The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosis.
Masarova L; Verstovsek S
Clin Adv Hematol Oncol; 2019 May; 17(5):299-307. PubMed ID: 31188809
[TBL] [Abstract][Full Text] [Related]
30. Flow cytometry immunophenotypic analysis of Philadelphia-negative myeloproliferative neoplasms: Correlation with histopathologic features.
Ouyang J; Zheng W; Shen Q; Goswami M; Jorgensen JL; Medeiros LJ; Wang SA
Cytometry B Clin Cytom; 2015; 88(4):236-43. PubMed ID: 25557358
[TBL] [Abstract][Full Text] [Related]
31. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.
Vannucchi AM; Antonioli E; Guglielmelli P; Pardanani A; Tefferi A
Leukemia; 2008 Jul; 22(7):1299-307. PubMed ID: 18496562
[TBL] [Abstract][Full Text] [Related]
32. Patients with idiopathic myelofibrosis show increased CD34+ cell concentrations in peripheral blood compared to patients with polycythaemia vera and essential thrombocythaemia.
Andréasson B; Swolin B; Kutti J
Eur J Haematol; 2002 Apr; 68(4):189-93. PubMed ID: 12071933
[TBL] [Abstract][Full Text] [Related]
33. Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients.
Ruberti S; Bianchi E; Guglielmelli P; Rontauroli S; Barbieri G; Tavernari L; Fanelli T; Norfo R; Pennucci V; Fattori GC; Mannarelli C; Bartalucci N; Mora B; Elli L; Avanzini MA; Rossi C; Salmoiraghi S; Zini R; Salati S; Prudente Z; Rosti V; Passamonti F; Rambaldi A; Ferrari S; Tagliafico E; Vannucchi AM; Manfredini R
Leukemia; 2018 Feb; 32(2):438-449. PubMed ID: 28745329
[TBL] [Abstract][Full Text] [Related]
34. [Clinical Analysis of Driver Mutations in Patients with Ph Negative Myeloproliferative Neoplasms].
He ZP; Tian HY; Tan M; Wu Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):842-848. PubMed ID: 29950230
[TBL] [Abstract][Full Text] [Related]
35. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.
Passamonti F; Giorgino T; Mora B; Guglielmelli P; Rumi E; Maffioli M; Rambaldi A; Caramella M; Komrokji R; Gotlib J; Kiladjian JJ; Cervantes F; Devos T; Palandri F; De Stefano V; Ruggeri M; Silver RT; Benevolo G; Albano F; Caramazza D; Merli M; Pietra D; Casalone R; Rotunno G; Barbui T; Cazzola M; Vannucchi AM
Leukemia; 2017 Dec; 31(12):2726-2731. PubMed ID: 28561069
[TBL] [Abstract][Full Text] [Related]
36. The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.
Chen Y; Fang F; Hu Y; Liu Q; Bu D; Tan M; Wu L; Zhu P
PLoS One; 2016; 11(4):e0154183. PubMed ID: 27111338
[TBL] [Abstract][Full Text] [Related]
37. Clinical and molecular features of patients with prefibrotic primary myelofibrosis previously diagnosed as having essential thrombocythemia in Japan.
Edahiro Y; Araki M; Inano T; Ito M; Morishita S; Misawa K; Fukuda Y; Imai M; Ohsaka A; Komatsu N
Eur J Haematol; 2019 Jun; 102(6):516-520. PubMed ID: 30977935
[TBL] [Abstract][Full Text] [Related]
38. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
39. MPL immunohistochemical expression as a novel marker for essential thrombocythemia and primary myelofibrosis differential diagnosis.
Ponce CC; Chauffaille Mde L; Ihara SS; Silva MR
Leuk Res; 2012 Jan; 36(1):93-7. PubMed ID: 21752469
[TBL] [Abstract][Full Text] [Related]
40. Microarray and Proteomic Analyses of Myeloproliferative Neoplasms with a Highlight on the mTOR Signaling Pathway.
Čokić VP; Mossuz P; Han J; Socoro N; Beleslin-Čokić BB; Mitrović O; Subotički T; Diklić M; Leković D; Gotić M; Puri RK; Noguchi CT; Schechter AN
PLoS One; 2015; 10(8):e0135463. PubMed ID: 26275051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
